T V De v eloping No v el Sol ut ion s To T r ea t H u man Papilloma - - PowerPoint PPT Presentation

VITTAIL

T V

Ltd.

Targeting Major Unmet Medical Needs

A first in class, small molecule inhibitor of a key protein (E6AP) Developed to preclinical stage prior to licensing Protected by intellectual property, including composition of matter patent(s)

Therapeutic development based on a key discovery by the founders:

The Company is targeting treatments for prostate cancer and HPV-related cancers that will be: a. b. c.

Risk minimised through:

Experienced management team (drug discovery methodology, global innovators of the underlying knowhow) Experienced Board with extensive biotech start-up and development track record Identification of key biomarkers and the clinical nexus between E6AP and multiple cancer Established contracts with key service providers (SYNthesis Research, Peter Mac). Established collaborations for disease models and clinical consultation Currently no competing IP

18% Prostate

88% Anus 41% Vagina and Vulva 44% Oral and Larynx 31% Oral and Pharynx Penis 51% 88% Cervix

Life expectancy HPV Related Cancers Cervical Cancer Oral cavity and Larynx Anal Cancer Oral Cavity and Pharynx Cancer 528,000 358,000 40,000 95 % 44% 88% 67.1% - all cases 17.3% - metastatic disease 60.7% - all cases 34.3% - metastatic disease 67% - all cases 30% -metastatic disease Global New Cases (pa) Percentage of Cancers Treatable by Vittail Vaginal and Vulvar Cancers Penile Cancer # Other Cancers Prostate Cancer 49,000 26,000 Global New Cases (pa) 41% 51% 18% 96,000 200,000 31% Percentage Treatable by Vittail

5 year survival

64.5% - all cases 38.5% - metastatic disease 95% - all cases 73% - metastatic disease Life expectancy 5 year survival 98.6% for all 29.8% metastatic disease 72.1% - all cases 17.4% - metastatic disease

Market Size

Target Markets

Tom Peat, Ph.D. John Deadman, Ph.D.

BSc in medicinal chemistry, PhD in the field of drug discovery. Over 25 years experience in Drug Discovery and Development. Managed multidisciplinary teams globally for research projects and regulatory purposes under GMP. Developed drugs under IND to Phase III clinical trials. Experience at management and board level in biotech in Europe, Australasia and China. International biotech consultant with multiple publications, grants and inventions (multiple patents including granted patents).

Founders: Experienced Innovators

VITTAIL has an experienced clinical advisory panel including:

• Prof. S. Sandhu for castration resistant prostate cancer
• Prof. B. Solomon for HPV driven cancers

BS in Biochemistry and Biophysics - UC Berkeley; PhD in Molecular, Cellular & Biophysical Studies - Columbia University. First scientist hired by SGX Pharmaceuticals, appointed Director of Structural Biology. VP of Proteomics at OpenEye Scientific Software, established San Diego facility. Established in CSIRO fragment screening program: used by multiple international biotech and pharmaceutical companies. Helped develop inhibitors: PRMT5 sold to Merck USA in 2016 for US$500M, other inhibitors sold to Pfizer in 2018 for US$490M. Experienced in solving >1000 protein structures, multiple publications & co-founder of MecRX & Vittail. PhD - Walter and Eliza Hall, discovered Bmi1; postdoctoral research at the Weizmann Institute; Major discovery of the degradation

• f p53 by Mdm2.

World-leading researcher in tumour suppression with a focus on cancer biology of the ubiquitin proteasome system. Led 2 large consortia (Europe and Australia with over $27m in research funding), supervised over 80 students/research staff. Multiple awards/fellowships (including NHMRC and the Victorian Endowment for Science Knowledge and Innovation).

Ygal Haupt, Ph.D.

SAB

Fragment-Based Drug Design (FBDD) screening process Partner Organisations’ Roles

Biological assays AlphaScreen activity/counter- screen/selectivity) ubiquitination, pre-clinical mouse models Medicinal chemistry Fragment optimisation physicochemical optimisation (ADMET/ “drug likeness”) X-ray crystallography Fragments and ligands using Australian Synchrotron Fragment Libraries Biophysical assays SPR and STD NMR Preclinical lead drug

CSIRO CSIRO Bio21 Synchrotron CSIRO PeterMac SYNthesis CDCO VITTAIL

The Target: E6-Associated Protein (E6AP)

E6AP is critical for high-risk HPV-related and prostate cancers E6AP ordinarily regulates the expression of three key tumour suppressors in the body - p53, PML and p27. In cancers E6AP is ‘over activated’ causing the destruction of tumour suppressors. VITTAIL’s therapeutic approach is to inhibit E6AP to restore the body’s tumour suppressive capacity.

E6AP promotes cancer by degrading the patient’s tumour suppressing protein (PML) in prostate cancer

Prostate

20 40 60 80 100

Lymphoma Germ Cell Lung Breast Colon CNS Complete Loss Partial Loss Major cancers in which the key target of E6AP is lost. These are relevant cancers for VITTAILS’s novel therapeutic approach

Targeting E6AP inhibits prostate cancer prolonging the life of experimental mice.

The growth of human prostate cancer is significantly inhibited by depleting E6AP in experimental models. Depletion of E6AP restores the body’s anti-cancer activities.

With E6AP Without E6AP

Timeline for Drug Development

Capital-efficient structure & key discovery partnership with CSIRO provides a rapid path to a commercialisation event

Assay Platform Establishment Fragment Screen Multiple Hits/Early Leads Identified Licensing event Compound Optimization Test Compound as E6AP inhibitor in cancer models Negotiate Licensing transaction/ M&A 2024 2020-21 2021-2022 2023 Proof

• f concept

data

Offer Summary

Amount to be Raised Offer Price Per Prefence Share Number of New Preference Shares Being Offered Valuation of ViITTAIL pre-raising $1.5 Million (with the ability to accept over subscriptions) Total Number of Shares After Raising (including Ordinary Shares and Preference Shares) Indicative Capitalisation of Company After Raising $1 1.5 Million (with the ability to accept over subscriptions) $1.5 Million 2 Million Preference Shares 1 Million Ordinary Shares Additional shares will also be issued if there are any

• versubscriptions

$3 Million